VII Simposio Internacional de Ciencias Farmacéuticas 2019 "VII SICF" -VII Simposio "Diseño, Obtención y Desarrollo de Fármacos"

VII Simposio Internacional de Ciencias Farmacéuticas 2019

VII SICF

DEVELOPMENT OF A STABLE BIOPHARMACEUTICAL FORMULATION FOR A MONOCLONAL ANTIBODY aHER2

Resumen [ES]

The development of pharmaceutical formulations of monoclonal antibodies is of vital importance to achieve effective and safe drugs. Hence, many research groups have focused on using different screening strategies to optimize the formulation for each antibody under study. Within the excipients used to carry out the screening of formulation are carbohydrates, salts, surfactants and amino acids. In our work we focused specifically on a monoclonal antibody aHer2 for the treatment of breast cancer type Her2 positive. For the characterization of these formulations were used methods such as dynamic light scattering, size exclusion chromatography, UV spectrophotometry, among others. As results of the work, was demonstrated the effectiveness of the stepwise screening methodology to select the best formulation variants. In addition, the presence of excipients as carbohydrates improves the stability of the formulation unlike the presence of sodium chloride.

Resumen [EN]

The development of pharmaceutical formulations of monoclonal antibodies is of vital importance to achieve effective and safe drugs. Hence, many research groups have focused on using different screening strategies to optimize the formulation for each antibody under study. Within the excipients used to carry out the screening of formulation are carbohydrates, salts, surfactants and amino acids. In our work we focused specifically on a monoclonal antibody aHer2 for the treatment of breast cancer type Her2 positive. For the characterization of these formulations were used methods such as dynamic light scattering, size exclusion chromatography, UV spectrophotometry, among others. As results of the work, was demonstrated the effectiveness of the stepwise screening methodology to select the best formulation variants. In addition, the presence of excipients as carbohydrates improves the stability of the formulation unlike the presence of sodium chloride.

Sobre el ponente

Yaiko Saddan Hernández Terrero

MsC. Yaiko Saddan Hernández Terrero

Centro Inmunología Molecular Flag of Cuba
Información Práctica
English (US)
No definido
30 minutos
No definido
Autores
Katya R. de La Luz
MsC. Yaiko Saddan Hernández Terrero
Julio F. Santo Tomas
Olga L. Fernández
Mileydis Sánchez
Palabras clave
aher2
biopharmaceutical
characterization
formulation
monoclonal antibody
screening